Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Danziten Patent Expiration

Danziten is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 18, 2040. Details of Danziten's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11793809 Pharmaceutical compositions of nilotinib
Feb, 2040

(14 years from now)

Active
US10874671 Pharmaceutical compositions of nilotinib
Feb, 2040

(14 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Danziten is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Danziten's family patents as well as insights into ongoing legal events on those patents.

Danziten's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Danziten's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 18, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Danziten Generics:

There are no approved generic versions for Danziten as of now.





About Danziten

Danziten is a drug owned by Azurity Pharmaceuticals Inc. Danziten uses Nilotinib Tartrate as an active ingredient. Danziten was launched by Azurity in 2024.

Approval Date:

Danziten was approved by FDA for market use on 07 November, 2024.

Active Ingredient:

Danziten uses Nilotinib Tartrate as the active ingredient. Check out other Drugs and Companies using Nilotinib Tartrate ingredient

Dosage:

Danziten is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 71MG BASE TABLET Prescription ORAL
EQ 95MG BASE TABLET Prescription ORAL